Follow our Journeys
Sharing success stories internal to Duke Capital Partners and external to our portfolio companies.
Duke University researchers have developed a gel-based cartilage substitute
Implants made of the material are currently being developed by Duke Capital Partners portfolio company Sparta Biomedical and tested in sheep. Researchers are gearing up to begin clinical trials in humans next year.
Read More about Duke University researchers have developed a gel-based cartilage substitute
Duke Capital Partners portfolio company, xilis, has closed a $19M+ extension to its Series A financing
xilis is a pioneering biotech company developing its MicroOrganoSphereTM (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development.
InnAVasc Medical, Inc., a Duke Capital Partners portfolio company, has been acquired by W. L. Gore & Associates.
InnAVasc, a Duke Capital Partners portfolio company, has been acquired by W. L. Gore & Associates. Gore will add InnAVasc's dialysis graft tech to its medical advanced materials unit.
Elle Magazine interviews adyn founder Dr. Elizabeth Ruzzo
Congratulations to Duke University alumna Elizabeth Ruzzo, PhD and the entire adyn team on the commercial launch of The Birth Control Test. Read the coverage in ELLE Magazine.
Read More about Elle Magazine interviews adyn founder Dr. Elizabeth Ruzzo
Associate Spotlight: Victoria Seskin
Fuqua Alumna Victoria Seskin '20 Credits Her Time as a DAN Associate With Helping Her Land Post-MBA Investing Job
restor3d Raises $23 Million
The money will be used to expand the delivery of 3D printed personalized surgical solutions across multiple musculoskeletal specialties and to develop machine learning software tools for assisting engineers with patient specific implant design.